Avalotcagene ontaparvovec

昂伐卡基

Report date: 2023/10/26 16:21:20

Base Information

Drug NameAvalotcagene ontaparvovec
Drug Alias NamescAAV8OTCDTX-301
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2/8 vector
Mechanisms of ActionOTC gene transference
TargetsOrnithine carbamoyltransferase
Therapy Area/IndicationsOrnithine Carbamoyltransferase Deficiency Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUltragenyx Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesUltragenyx Pharmaceutical Inc
Inactive CompaniesN/A
Active IndicationsOrnithine Carbamoyltransferase Deficiency Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A